Project Grant K01DA060359
Award Date
1/1/25
Completion Date
12/31/29
Dollars Obligated
$196K
Federal Agency
National Institute on Drug Abuse
Federal Grant Program
93.279
Assistance Type
Project Grant
Place of Performance
Spokane, WA 99202, USA
Similar Awards
This Project Grant award from the National Institute on Drug Abuse (NIDA), under the Drug Use and Addiction Research Programs (CFDA 93.279), provides $715,238.00 to the University of California, San Diego (UCSD) to conduct a multivariate genome-wide association analysis of opioid-related traits in a diverse population of 500,000 individuals. The goal is to improve understanding of the genetic basis of opioid use disorder (OUD) and related pre-addiction stages, such as initial opioid use,...
This federal Project Grant award from the National Institute on Drug Abuse (NIDA), under the Drug Use and Addiction Research Programs (CFDA 93.279), is funding the development of a novel epigenetic regulator as a potential treatment for opioid use disorder (OUD). The grantee, Epivario Inc., a for-profit biotechnology research organization, will screen a new class of ACSS2 inhibitors and evaluate their efficacy in preclinical animal models of OUD. Specifically, the $275,253 award will support...
The federal Project Grant award with ID DP2DA062283 was provided by the National Institute on Drug Abuse (NIDA) under the Drug Use and Addiction Research Programs (CFDA 93.279). The $2,542,500 grant, awarded on September 1, 2024, will support the development of novel econometric methods and a unified framework for integrating real-world evidence (RWE) to analyze inconclusive randomized controlled trials (RCTs) focused on opioid use disorder (OUD) treatments. The project, to be conducted by Weill...
This Project Grant award from the National Institute on Drug Abuse (NIDA), under the federal Drug Use and Addiction Research Programs (CFDA 93.279), aims to develop high-precision epigenetic therapeutics for treating opioid use disorder (OUD). The $398,137 award to Boston Interactome LLC, effective May 1, 2025 through April 30, 2026, will fund research to identify functional modulators of the G9A epigenetic protein complex that regulates DFosB expression under chronic opioid exposure. The goal...
This federal Project Grant award of $4,665,000 was provided by the National Institute on Drug Abuse (NIDA) under the Drug Use and Addiction Research Programs (CFDA 93.279) to the University of Washington. The award will fund the development and testing of a novel "Community-Based Opioid Treatment (CBOT)" implementation strategy to deliver buprenorphine for opioid use disorder treatment and HIV prevention/care services to people who use opioids. The project will involve two parts -...
This Project Grant award from the National Institute on Drug Abuse (NIDA), under the Drug Use and Addiction Research Programs (CFDA 93.279), provides $233,250 to The Washington University in St. Louis to examine the relationship between early cannabis use and later opioid use disorder. The key objectives are to: 1) Estimate the association between early cannabis use and both proximal and distal aspects of opioid involvement, including whether the relationships are modified by co-occurring...
This Project Grant award of $2,415,940.00, awarded by the National Institute on Drug Abuse (NIDA) under the Drug Use and Addiction Research Programs (CFDA 93.279), supports research to develop digital biomarkers and phenotypes for tracking craving patterns in individuals with opioid use disorder (OUD) during medication-based treatment (MOUD). The award will fund a prospective, observational trial of 300 participants initiating MOUD with buprenorphine, methadone or naltrexone. Continuous wearable...
This $1,264,863 Project Grant awarded by the National Institute on Drug Abuse (NIDA) under the Drug Use and Addiction Research Programs (CFDA 93.279) will fund research to evaluate the efficacy and neural mechanisms of combining the medication guanfacine (GXR) and the behavioral intervention Mindfulness Oriented Recovery Enhancement (MORE) as an adjunct to buprenorphine maintenance for individuals with opioid use disorder (OUD). The research will be conducted by Rutgers, The State University...
The National Institute on Drug Abuse (NIDA) awarded a $326,410 Project Grant under the Drug Use and Addiction Research Programs (CFDA 93.279) to Berkshire Biomedical Corporation in Dallas, TX. The grant will fund a two-phased clinical study to evaluate the feasibility, acceptance, and impact on treatment retention of a hand-held, automated, personalized oral liquid dispensing system (COPA) for delivering take-home methadone to patients with opioid use disorder. The initial single-site pilot...
The National Institute on Drug Abuse (NIDA), under CFDA Program 93.279 - Drug Use and Addiction Research Programs, awarded a $1,965,600 Project Grant to the Regents of the University of Colorado, doing business as the University of Colorado-Denver. The grant titled "Precision Pharmacogenomics and Indigenous Research: A Novel Approach to Tobacco Cessation Efficacy in American Indian Communities" aims to leverage genome-wide and epigenome-wide association studies to better understand the...